FDA Approved: DANZITEN — Supplemental Application (Azurity Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Danziten (nilotinib) submitted by Azurity Pharmaceuticals, Inc. The supplement adds to the existing NDA for the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia

Drugs mentioned

• DANZITEN (NILOTINIB)

Snippet

SUPPL AP for DANZITEN (NILOTINIB)